The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Mylan's 2012 sales performance.
The new CEO has been given an early gift as she steps into the role by the FDA, which just rejected Mylan's application to market a generic version of
Mylan deal with Roche clears path to biosimilar Herceptin launch. Covers global markets with the exception of Japan, Brazil and Mexico. ... After months of wrangling in the courts, Mylan and Roche have agreed a licensing deal that should allow a
|CNS revenue 2014|
|2: Biogen Idec|
|6: Johnson & Johnson|
|8: Merck KGaA|
|11: Bristol-Myers Squibb|
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com